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A b s T r A C T
background: Helicobacter pylori infection causes 
lifelong gastritis and is associated with the development 
of peptic ulcer disease, MAlT lymphoma and gastric 
cancer. Many patients benefit from H. pylori eradication 
therapy. PPi-triple therapy is recommended as initial 
therapy. Quadruple therapy, with a PPi, bismuth, and 
two antibiotics, used to be recommended as second-line 
therapy, but can no longer be prescribed because bismuth 
is no longer available. Therefore, there is an urgent need 
for new effective rescue therapies. levofloxacin-based 
therapies were suggested as an alternative to quadruple 
therapy. The aim of this study is to examine the efficacy 
and tolerability of such a one-week therapy with levofloxacin 
and esomeprazole combined with either amoxicillin or 
clarithromycin in a dutch population. 
Methods: between february 2005 and November 2006, 123 
consecutive H. pylori positive patients were enrolled in this 
study. The first 59 patients were treated with esomeprazole, 
amoxicillin and levofloxacin (group i). The next 64 patients 
were treated with esomeprazole, clarithromycin, and 
levofloxacin (group ii). both therapies were compared for 
efficacy and tolerability.
results: in group i the overall (iTT) cure rate was 96% and 
in group ii it was 93%. Minor side effects occurred in 29% 
of patients in group i and in 41% of patients in group ii. 
Major side effects that warranted discontinuation of therapy 
occurred in two patients in group ii. 
Conclusion: seven-day triple therapy with esomeprazole, 
levofloxacin and either amoxicillin or clarithromycin 
for seven days is very effective and safe for H. pylori 
eradication. The combination with amoxicillin seems to be 
better tolerated than the combination with clarithromycin. 
K E Y W o r d s
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i N T r o d U C T i o N
Helicobacter pylori infection causes life-long gastritis and 
is associated with the development of peptic ulcer disease, 
mucosa-associated lymphoid tissue (MALT) lymphoma, 
and gastric cancer.1 Some dyspeptic patients and even 
asymptomatic persons benefit from H. pylori eradication 
therapy. Most experts believe that eradication of H. pylori 
may possibly prevent gastric cancer.2,3 There are several 
well-investigated eradication therapies available. The ideal 
therapy for this common infection should be simple, safe, 
cheap, well-tolerated and of short duration, and above all it 
should reach a high cure rate. 
Most guidelines, including the Dutch Institute for 
Healthcare Improvement (CBO)/Dutch College of General 
Practitioners (NHG) guideline ‘Gastric complaints’,4 advise 
triple therapy with a proton pomp inhibitor (PPI) and 
two different antibiotics for an initial attempt at H. pylori 
eradication. After a first antibiotic treatment, a urea breath 
test to test for cure is usually recommended. In case of 
persisting infection, the guidelines recommend the use 
of quadruple therapy, which contains a PPI, bismuth 
subcitrate and two different antibiotics.5-11 Although this 
therapy has the disadvantage of a complicated dosing 
regimen, it is very effective and is even considered to be a 
first-line treatment in some countries. 
However, unfortunately, in the Netherlands and many 
other European countries, bismuth is no longer available 
and quadruple therapy can therefore no longer be 
prescribed. A possible solution could be the use of a new 
single multi-drug anti-Helicobacter capsule that contains 
bismuth, tetracycline and metronidazole, but even though 
this drug has now been approved by the FDA it has not 
yet received approval from the European authorities to 
enter the market.12 Hence, there is an urgent need for new 
effective therapies in the Netherlands, especially for backup 
after failure of a first-line PPI-triple therapy. 
Levofloxacin is a fluoroquinolone antibacterial agent with 
a broad spectrum of activity against both Gram-positive 
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and Gram-negative bacteria as well as atypical respiratory 
pathogens.13 Several studies demonstrated the efficacy of 
levofloxacin in the treatment of infection of the respiratory 
tract, genitourinary tract, skin and skin structures.13 
The antibacterial activity coupled with its excellent 
bioavailability and ease of dosing make levofloxacin an 
attractive antibiotic for treatment of H. pylori infection. 
Recently, some studies have reported excellent results 
with the use of levofloxacin in H. pylori eradication, not 
only as first-line therapy but also as second line and as 
rescue therapy.14-29 In association with other antibiotics, 
levofloxacin reached high H. pylori eradication rates 
(often over 90%) with a low incidence of side effects. All 
eradication studies with levofloxacin were performed in 
other countries than the Netherlands and these data need 
confirmation in our country.30,31 Therefore, the aim of the 
present study is to examine the efficacy and tolerability 
of a one-week therapy with levofloxacin, esomeprazole 
and either amoxicillin or clarithromycin in a Dutch 
population. 
P A T i E N T s  A N d  M E T H o d s
Between February 2005 and November 2006, 123 
consecutive H. pylori positive patients who visited 
Bernhoven Hospital (Oss) due to dyspepsia, with or 
without ulcer disease, were enrolled in this open-label 
study. Bernhoven Hospital is a non-academic community 
hospital in the southeast of the Netherlands. In all 
patients, H. pylori status was determined by analysis 
of gastric biopsies or through a well-validated 13C urea 
breath test (BreathIDTM, Oridion Systems).32 The first 
59 patients were treated with esomeprazole 40 mg 
(Nexium®), amoxicillin 1000 mg and levofloxacin 500 mg 
(Tavanic®), all given twice daily for seven days (Group I). 
The next 64 patients were treated with esomeprazole 40 
mg (Nexium®), clarithromycin 500 mg, and levofloxacin 
500 mg (Tavanic®), all given twice daily for seven days 
(Group II). Patients were instructed to take their treatment 
precisely as prescribed and were informed about possible 
side effects. Furthermore, patients were asked whether 
they had undergone previous attempts to eradicate H. 
pylori or whether they had received pretreatment with a 
PPI. At least five weeks after finishing therapy, H. pylori 
status was tested again with either biopsy-based tests 
if endoscopy was clinically indicated or otherwise with 
the 13C urea breath test. Side effects were recorded by 
the treating physician at the end of the treatment and 
graded on a five-point, internationally accepted scale, 
which we have described before. This scale contains five 
categories, ranging from ‘no adverse effects’ (category 
A), ‘slight discomfort not interfering with daily activities’ 
(category B), ‘moderate adverse effects interfering with 
daily activities’ (category C), ‘severe adverse effects, work 
not possible’ (category D), to ‘severe adverse affects, 
discontinuation of treatment’ (category E).33 The two 
therapies were compared for efficacy and tolerability. 
Upper gastrointestinal endoscopy
A subgroup of patients underwent upper gastrointestinal 
endoscopy. During endoscopy seven biopsies were taken. 
Four (2 antrum and 2 corpus) for histology, two (1 antrum 
and 1 corpus) for two separate CLO-tests® and one (1 
antrum) for culture. Patients were considered H. pylori 
positive if one of these three different tests on either 
antrum or corpus biopsies was positive.
13Urea breath test
Another subgroup of patients had a H. pylori urea breath 
test (BreathIDTM from Oridion Systems, a commercially 
available and well-validated near-patient 13C-urea breath 
test), instead of endoscopy.32 Care was taken to ensure 
that patients had not taken any PPIs for at least one week 
before the urea breath test. Breath samples were recorded 
as positive if the 13CO2/
12CO2 ratio was above 5‰. Values 
below the 5‰ cut-off were considered to be H. pylori 
negative. This test provides excellent sensitivity and 
specificity in diagnosing H. pylori infection, both before 
and after H. pylori eradication.
statistical analysis
Baseline characteristics of both patient groups were 
compared using the Student’s t-test or χ2 square test 
where appropriate. H. pylori eradication rates with 95% 
confidence intervals were calculated and compared using 
the χ2 test. This analysis was repeated for the subgroup of 
patients with a prior (failed) attempt to eradicate H. pylori. 
For analyses the SAS® statistical software package (SAS 
Institute Inc., USA) was used. Statistical significance was 
defined as a p value <0.05. Missing values were excluded 
from analyses.
r E s U l T s
Population
A total of 123 consecutive H. pylori positive patients (mean 
age 53 (SD 16), 44% male,) were included between February 
2005 and November 2006. Twenty-seven of these patients 
had a diagnosis of peptic ulcer disease (22%). The first 
59 patients were treated with esomeprazole, amoxicillin 
and levofloxacin (group I), the following 64 patients with 
esomeprazole, clarithromycin and levofloxacin (group II). 
Table 1 shows that, although not randomised, both patient 
groups had similar baseline characteristics. However, 
there were more patients with a history of failed H. pylori 
eradication in group I.
98
m a r c h  2 0 0 9 ,  V o l .  6 7 ,  N o .  3
Schrauwen, et al. Seven-day PPI-triple therapy with levofloxacin for Helicobacter pylori eradication.
Effectiveness of H. pylori eradication
Of the 59 patients treated with esomeprazole, amoxicillin 
and levofloxacin, 57 were cured of their H. pylori infection, 
yielding a 97% cure rate (95% CI 92 to 100%), both for 
intention-to-treat (ITT) and per protocol (PP) analysis. Of 
the 64 patients treated with esomeprazole, clarithromycin 
and levofloxacin, 59 had successful H. pylori eradication, 
yielding an ITT cure rate of 92% (95% CI 86 to 99%) and 
a PP cure rate of 95% (95% CI 90 to 100%) (p value for 
difference ITT 0.29; PP 0.69) )(table 2).
If only patients with first-line therapy were included 
ITT cure rates were 43/45 (96%, 95% CI 91 to 100%) 
for patients treated with esomeprazole, amoxicillin and 
levofloxacin and 55/59 (93%, 95%CI 87 to 100%) for 
patients treated with esomeprazole, clarithromycin and 
levofloxacin (p value for difference: 0.61).
If only patients with second/third-line therapy were 
included ITT cure rates were 14/14 (100%) for group I and 
4/5 (80%) for group II (p value for difference 0.09).
side effects
Both regimens were well tolerated, although in the regimen 
with clarithromycin discontinuation of treatment occurred 
in two patients. Reasons for discontinuation were nausea in 
one and rupture of an Achilles tendon in the other patient. 
When tested, neither of these patients were cured of their 
infection. Minor side effects occurred in 29% of all patients 
in group I and in 41% of all patients in group II (p=0.17). 
Diarrhoea was the most common side effect.
d i s C U s s i o N
The results of this study show that levofloxacin can be 
used safely for eradication of H. pylori. They also show 
that its use leads to high cure rates in Dutch patients. A 
limitation of the present study is that it is not a blinded 
randomised clinical trial. However, treatment allocation 
was determined only by the date of inclusion, not by patient 
characteristics. This is confirmed by the comparable 
baseline characteristics of both groups. Furthermore, cure 
of H. pylori infection is a solid, well-defined endpoint and 
open studies like ours are well accepted in this field in 
order to identify new treatment options. 
The triple therapy with esomeprazole, amoxicillin and 
levofloxacin reached a 96% (43/45) per protocol cure rate 
when used as initial therapy. With the identical therapeutic 
regimen in primary treatment Antos et al. cured 28/30 of 
patients (93.3%) in France.22 Retreatment after failure of 
an initial anti-Helicobacter therapy is generally considered 
to be more difficult than initial therapy, but when we 
employed this triple drug therapy as second-line therapy 
in eight patients and as third-line therapy in six patients 
it was successful in all these patients. Most studies in the 
literature also deal with the use of levofloxacin in second- 
or third-line therapy.
Several studies have directly compared different 
levofloxacin-based combinations with several different 
quadruple combinations in retreatment. Two systematic 
reviews and meta-analyses have summarised these studies, 
Table 1. Baseline characteristics
levofloxacin, esomeprazole and amoxicillin
(n=59)
levofloxacin, esomeprazole and clarithromycin
(n=64)
P value for 
difference
Mean age 55 years (SD 15) 52 years (SD 16) 0.26
Male gender 26 (44%) 28 (44%) 0.97
Smoking 17 (29%) 20 (31%) 0.77
PPI-pretreatment 18 (31%) 23 (36%) 0.53
Previous therapy failure 14 (24%) 5 (8%) 0.01
Body mass index 25.7 (SD 3.9) 26.1 (SD 4.5) 0.62
PPi = proton pomp inhibitor.
Table 2. Effectiveness of Helicobacter pylori eradication
levofloxacin, esomeprazole and  
amoxicillin (n=59)
levofloxacin, esomeprazole and  
clarithromycin (n=64)
P value for
difference
Helicobacter pylori eradicated (ITT) 57 (97%) 59 (92%) 0.29
Helicobacter pylori eradicated (PP) 57 (97%) 59 (95%) 0.69
Side effects 17 (29%) 26 (41%) 0.17
Cessation due to side effects 0 (0%) 2 (3%) 0.17
2nd/3rd line therapy (ITT) 14/14 (100%) 4/5 (80%) 0.09
First-line therapy (ITT) 43/45 (96%) 55/59 (93%) 0.61
iTT = intention to treat; PP = per protocol.
99
m a r c h  2 0 0 9 ,  V o l .  6 7 ,  N o .  3
Schrauwen, et al. Seven-day PPI-triple therapy with levofloxacin for Helicobacter pylori eradication.
and the data suggest that the levofloxacin-based regimens 
were a good alternative to quadruple therapy.16,20 In 
fact, levofloxacin containing treatments had superior 
cure rates as compared with the standard quadruple 
regimens.16,20,34 The cure rates achieved with levofloxacin 
in these studies, however, were somewhat lower then the 
>95% we have achieved in our study.16,20 Furthermore, one 
study suggested that the levofloxacin-based triple therapy 
was also superior to rifabutin-based triple therapy, which 
is another established rescue therapy.23 Our excellent 
result with esomeprazole, amoxicillin and levofloxacin for 
retreatment in patients who failed to be cured with their 
previous therapy therefore supports this large body of 
data from the literature.14-20,22-29,35 The triple therapy with 
esomeprazole, clarithromycin and levofloxacin reached 
a 96% (55/57) per protocol cure rate when used as initial 
therapy. At present, triple therapy with a PPI, amoxicillin 
and clarithromycin is usually our primary therapy. After 
failure of this regimen bacteria resistant to clarithromycin 
are usually encountered, whereas resistance to amoxicillin 
is extremely rare.30,31 Amoxicillin can therefore be used 
in retreatment, but microbiologically it is not logical to 
use clarithromycin again in retreatment. Nevertheless, 
we cured four out of five patients who had previously 
failed a PPI, amoxicillin and clarithromycin combination 
with regimen II. Few studies are available regarding 
the combination of levofloxacin with clarithromycin or 
another macrolide.24,28 Randomised head-to-head studies 
of regimen I vs regimen II are unavailable. However, 
theoretically, primary clarithromycin resistance might 
have a negative impact on the cure rates of the regimen we 
used in group II.
At the moment it is not clear whether levofloxacin should 
be used in seven or ten-day regimens. Some authors have 
consistently used ten-day therapies and meta-analysis 
showed this to be superior to seven-day therapy.16,20 Our 
results with seven days of treatment in Dutch patients are 
already >95% and therefore we do not promote increasing 
the length of treatment from seven to ten days for the 
Dutch situation. Most Italian ten-day studies used a lower 
dose of levofloxacin, either 500 mg once daily or 250 mg 
twice daily. Others and we chose a higher dose of 500 mg 
twice daily for seven days and this has been shown to be 
a well-tolerated and safe dosage schedule.21 Therefore, we 
would at present not recommend using a lower dose.20 
A possible threat to the efficacy of levofloxacin is the 
presence of antimicrobial resistance to fluoroquinolones.31 
The prevalence of this resistance has been determined in 
only a limited number of studies. The only Dutch data date 
back to 1999, when Debets-Ossenkopp reported a primary 
resistance rate of trovafloxacin of 4.7%.36 In France, 
resistance to fluoroquinolones increased from 3.3% in 1999 
to 17.5% in 2003.37 In 2006, it was reported to be 16.8% in 
Belgium.38 The high rate of resistance in these countries 
probably mirrors the increasing use of quinolones to treat 
various common infections.39 A well-documented much 
lower use of quinolones in the Netherlands40 as compared 
with France and Belgium probably results in lower levels of 
fluoroquinolone resistance in Dutch patients. This might 
also explain why our cure rates are at the top of what is 
reported in the literature. The higher dose of levofloxacin, 
however, is another possible explanation for our relatively 
high cure rate. 
Levofloxacin as an antibiotic is generally well tolerated.13 
Overall in our study adverse effects were reported by 35% of 
the patients, but these were most often mild. Twenty-nine 
percent of patients in group I reported side effects, but they 
did not lead to discontinuation in any of these patients. 
Forty-one percent of patients in group II, a higher number 
in comparison with group I, reported side effects. In two 
patients, treatment was discontinued, because of extreme 
nausea and an Achilles tendon rupture. The latter is 
a known, but rare and severe complication, but in our 
patient, a 70-year-old man, it healed and had no long-term 
consequences. According to an investigation in the United 
States tendon rupture occurs in less than four per million 
prescriptions of levofloxacin,41 and it should not therefore 
be a reason to fear the use of this antibiotic. Based on our 
data it appears that the combination of levofloxacin with 
amoxicillin is better tolerated and causes fewer side effects 
then the combination of levofloxacin with clarithromycin.
Then, based on our own experience and our review of 
the literature, what should be the place of levofloxacin in 
Helicobacter therapy in the Netherlands? According to 
the Dutch CBO/NHG consensus a triple therapy with a 
PPI, amoxicillin and clarithromycin should be the initial 
regimen for treating H. pylori infection in the Netherlands. 
Janssen et al. recently reported the prevalence of H. pylori 
antibiotic resistance in the east of the Netherlands. This 
study shows that primary metronidazole resistance was 
stable throughout the study period (1997-2002) with 
a mean prevalence of 14%. The prevalence of primary 
clarithromycin resistance was still very low (mean 
prevalence 1%).42 Therefore, a regimen with amoxicillin 
and clarithromycin is a logical and microbiologically 
sound choice for an initial anti-Helicobacter therapy in 
the Netherlands and it should probably remain our initial 
therapy. It leads to high cure rates and with these high cure 
rates it is almost impossible to demonstrate superiority 
with another therapy. An Italian study showed superiority 
of the regimen we used in group II over standard PPI-triple 
therapy, but resistance against clarithromycin is much 
higher in Italy than in the Netherlands.21 Levofloxacin-based 
therapies are an alternative for primary treatment in the 
Netherlands. However, we would not yet recommend 
them as initial therapy, especially since data on primary 
fluoroquinolone resistance of H. pylori in the Netherlands 
are not yet available.
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According to the guidelines, all patients who received 
initial therapy should be tested for cure if urea breath 
testing is available. Patients also have a desire to know 
whether or not they are truly cured.8,4,25,43 Quadruple 
therapy is recommended in the Dutch guideline as 
back-up therapy4 but bismuth (De-Nol® or Ranitidine 
Bismuth Subcitrate (Pylorid®)) is no longer available. In 
this situation it seems logical to accept a levofloxacin-
based regimen as a universal second-line therapy. 
Those who are not cured after an initial attempt can 
be retreated with the esomeprazole, amoxicillin, and 
levofloxacin regimen that we employed in group I. In 
case of penicillin allergy it is advisable to initially use a 
seven-day combination of a PPI, clarithromycin 250 mg or 
500 mg, and metronidazole 500 mg, all twice daily. If this 
fails, the levofloxacin regimen we used in group II can 
be used as rescue therapy. A triple therapy of a PPI with 
levofloxacin and tinidazole (500 mg twice daily) might be 
an alternative in this setting.29
C o N C l U s i o N
Seven-day triple therapy with esomeprazole, levofloxacin 
and either amoxicillin or clarithromycin is very effective 
and safe for H. pylori eradication in the Netherlands. 
These regimens can be used as first-line therapy 
and as second-line therapy. The combination with 
amoxicillin appears to cause fewer side effects. Regimens 
incorporating levofloxacin provide us with new and long 
awaited possibilities to treat H. pylori. Although it may be 
too early to promote their use as initial therapy we can, 
based on our data as well as the literature, already advise 
the use of these regimens for back up after failed initial 
therapy. 
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